Pharmacokinetics of Ruxolitinib in Patients with Atopic Dermatitis Treated With Ruxolitinib Cream: Data from Phase II and III Studies

BACKGROUND: Pathogenesis of atopic dermatitis (AD) involves the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway. A cream formulation of ruxolitinib, a potent selective JAK1/JAK2 inhibitor, was developed for topical delivery. METHOD: Pharmacokinetic data were obtain...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Am J Clin Dermatol
Hlavní autoři: Gong, Xiaohua, Chen, Xuejun, Kuligowski, Michael E., Liu, Xing, Liu, Xiang, Cimino, Evan, McGee, Ryan, Yeleswaram, Swamy
Médium: Artigo
Jazyk:Inglês
Vydáno: Springer International Publishing 2021
Témata:
Original Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8200345/
https://ncbi.nlm.nih.gov/pubmed/33982267
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40257-021-00610-x
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky